Clinical trial NCT02537496: Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS
Official title: Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Enhancement of Dorsolateral Prefrontal Cortex Neuroplasticity: A TMS-EEG Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alzheimer's Disease
Keywords: Alzheimer's Disease
Brain stimulation
Transcranial Magnetic Stimulation
Neuroplasticity
cognitive enhancement
TMS-EEG
rTMS
PAS
Lead sponsor: Centre for Addiction and Mental Health
Sponsor class: OTHER
Collaborators: name: Brain & Behavior Research Foundation
name: University of Toronto
First posted: 2015-09-01
Enrollment: 36
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be assigned randomly to a 4-week repetitive course of either rTMS or control intervention (Sham rTMS) that is similar to rTMS but does not produce the same amount of brain stimulation.
Primary purpose: TREATMENT

Brief summary: In this study the investigators aim at assessing and then enhancing neuroplasticity in the dorsolateral prefrontal cortex (DLPFC) and working memory - a key function of DLPFC - in patients with mild Alzheimer's disease (AD). The investigators will use Paired Associative Stimulation (PAS) paradigm to measure neuroplasticity and then a 4-week course of high-frequency repetitive Transcranial Magnetic Stimulation (rTMS) to the DLPFC to enhance cognitive function. Clinical and cognitive assessments will be done at baseline, one week, one month and 6 months after the rTMS course. Healthy controls will also be enrolled to carry out baseline cognitive assessments and a baseline measurement of neuroplasticity.

Detailed description: Specific aim 1: To assess working memory in participants with Alzheimer's disease (AD) and its change in response to a 4-week course of bilateral rTMS of DLPFC.

Hypothesis 1a: Compared to healthy individuals, participants with AD will be impaired on the N-back task.

Hypothesis 1b: Compared to sham rTMS, active rTMS will result in improvement on the N-back task in participants with AD at 1 week and 4 weeks after the treatment.

Specific aim 2: To assess DLPFC theta-gamma coupling during working memory performance in AD and its change in response to a 4-week course of bilateral rTMS of DLPFC.

Hypothesis 2a: Compared to healthy individuals, participants with AD will be impaired on DLPFC theta-gamma coupling during the N-back task.

Hypothesis 2b \& 2c: Compared to sham rTMS, active rTMS will result in improvement in DLPFC theta-gamma coupling during the N-back task in participants with AD at 1 week and 4 weeks after the treatment.

Specific aim 3: To assess DLPFC neuroplasticity using PAS in participants with AD and its change in response to a 4-week course of bilateral rTMS.

Hypothesis 3a: Compared to healthy individuals, participants with AD will be impaired on PAS-induced neuroplasticity.

Hypothesis 3b: Compared to sham rTMS, active rTMS will result in improvement on PAS-induced neuroplasticity in participants with AD at 1 week and 4 weeks after the treatment.

Specific aim 4: To assess change in working memory, theta gamma coupling and DLPFC neuroplasticity at 6 months after the course of bilateral rTMS.

Hypothesis 4: Compared to sham rTMS, active rTMS group will perform better on measures of working memory, theta gamma coupling and PAS- induced DLPFC neuroplasticity 6 months after the course of rTMS.

Specific aim 5: To assess the change in general cognitive function at 4 weeks and 6 months after the course of bilateral rTMS.

Hypothesis 5: Compared to sham rTMS, active rTMS group will perform better on measures of general cognitive function at 4 weeks and 6 months after the course of rTMS.

Specific Aim 6: To assess insight in AD at baseline and any change in insight at 4 week and 6 month post rTMS follow up. H6: Participants with AD will have impaired insight into illness and cognitive function and they will experience improved insight at 4 week and 6 month follow up points.

Specific Aim 7: To validate a new scale for insight in AD , 'The Scale to Assess Anosognosia in Neurocognitive Disorders' (SAND) for its ability to assess insight at baseline and any change at 4 weeks and 6 month follow up points. H7: In participants with AD, SAND will be able to assess insight into illness and cognitive function at baseline, and will be able to detect change in insight at follow up points.

Eligibility criteria: Inclusion Criteria for AD participants:

1. Age 55 years or above.
2. Ability to understand and speak English.
3. Confirmed Diagnosis of Probable AD by NIA-AA criteria.
4. Either not taking Cognitive enhancers or taking them at a stable dose for the last 3 months.
5. Willingness and ability to provide informed consent or an ability to assent and availability of a substitute decision maker willing to provide consent on participant's behalf.
6. Corrected visual acuity enough to read newspaper headlines.
7. Ability to hear a raised conversational voice, with hearing aids if needed.

Inclusion criteria for healthy control participants:

1. Age 55 or above.
2. Willingness and ability to speak English.
3. Willingness and ability to provide informed consent.
4. Corrected visual acuity enough to read newspaper headlines.
5. Ability to hear a raised conversational voice, with hearing aids if needed.

Exclusion Criteria for AD participants:

1. MOCA score \< 10.
2. DSM IV - TR diagnosis of a current episode of mood disorder in the last 3 months.
3. DSM IV - TR diagnosis of a current anxiety disorder in the last 3 months.
4. DSM IV - TR diagnosis of a current substance use disorder in the last 3 months.
5. DSM IV - TR diagnosis of a current or lifetime primary psychotic disorder.
6. Diagnosis of intellectual disability or a neurodevelopmental disorder.
7. Electroconvulsive Therapy treatment in the last 6 months.
8. History of a seizure other than a febrile seizure in infancy.
9. Currently taking Anticonvulsants or Benzodiazepines.
10. Any contraindication for TMS or any other medical condition/circumstances that would make the study participation difficult for the participant.

Exclusion criteria for healthy control participants:

1. Meets criteria for a DSM IV - TR diagnosis other than simple phobias or Adjustment disorder.
2. Any other neurological disorder affecting central nervous system.
3. Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks.
4. History of seizure other than a febrile seizure in infancy
5. Currently taking Anticonvulsants or Benzodiazepines.
6. Any contraindication for TMS or any other medical condition/circumstances that would make the study participation difficult for the participant.

Primary outcomes:
measure: Change in N-back Task Performance
timeFrame: pre-intervention (baseline) and then 7 days, 4 weeks and 6 months after intervention
Secondary outcomes:
measure: Changes in Theta Phase-Gamma Amplitude Coupling
timeFrame: Change from baseline at 7 days, 4 weeks and 6 months after intervention.
measure: Changes in DLPFC Neuroplasticity
timeFrame: Change from baseline at 7 days, 4 weeks and 6 months after intervention.
measure: Changes in Cognitive Function Measures Scores
timeFrame: Change from baseline at 7 days, 4 weeks and 6 months after intervention.
measure: Validating a new scale for insight in Alzheimer's disease.
timeFrame: Change from baseline at 7 days and 6 months after intervention.
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Center for Addiction and Mental Health
state: Ontario
Study officials:
affiliation: Center for Addiction and Mental Health
name: Sanjeev Kumar, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: